Amedisys Inc. (NASDAQ:AMED) was down 6.1% on Tuesday . The company traded as low as $51.64 and last traded at $51.64, with a volume of 176,223 shares traded. The stock had previously closed at $55.00.

A number of equities research analysts recently weighed in on AMED shares. Stephens started coverage on shares of Amedisys in a report on Thursday, June 16th. They issued an “equal weight” rating and a $55.00 target price on the stock. Mizuho restated a “buy” rating and issued a $57.00 target price (up previously from $49.00) on shares of Amedisys in a report on Monday, April 11th. Zacks Investment Research upgraded shares of Amedisys from a “hold” rating to a “buy” rating and set a $57.00 target price on the stock in a report on Monday, May 9th. Jefferies Group reiterated a “buy” rating and issued a $59.00 price objective on shares of Amedisys in a research note on Wednesday, May 25th. Finally, Royal Bank Of Canada increased their price objective on shares of Amedisys from $41.00 to $48.00 and gave the company a “sector perform” rating in a research note on Friday, May 6th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and four have given a buy rating to the company’s stock. Amedisys presently has a consensus rating of “Hold” and a consensus price target of $52.00.

The company has a market capitalization of $1.80 billion and a PE ratio of 46.56. The firm’s 50-day moving average price is $51.32 and its 200-day moving average price is $46.27.

Amedisys (NASDAQ:AMED) last issued its earnings results on Tuesday, May 3rd. The company reported $0.33 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.33. The firm earned $348.80 million during the quarter, compared to analysts’ expectations of $337.07 million. The firm’s quarterly revenue was up 15.7% on a year-over-year basis. During the same period last year, the firm posted $0.30 earnings per share. On average, analysts anticipate that Amedisys Inc. will post $1.74 earnings per share for the current fiscal year.

In related news, Director Bruce D. Perkins acquired 1,000 shares of the firm’s stock in a transaction dated Friday, May 13th. The stock was purchased at an average cost of $50.21 per share, with a total value of $50,210.00. Following the completion of the acquisition, the director now directly owns 10,354 shares of the company’s stock, valued at $519,874.34. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Scott G. Ginn sold 6,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 11th. The shares were sold at an average price of $51.62, for a total transaction of $309,720.00. Following the transaction, the insider now directly owns 48,009 shares of the company’s stock, valued at $2,478,224.58. The disclosure for this sale can be found here.

Other hedge funds and institutional investors recently added to or reduced their stakes in the company. Sei Investments Co. boosted its position in Amedisys by 1,922,350.0% in the fourth quarter. Sei Investments Co. now owns 38,449 shares of the company’s stock valued at $1,512,000 after buying an additional 38,447 shares during the last quarter. Rhumbline Advisers boosted its position in Amedisys by 5.3% in the fourth quarter. Rhumbline Advisers now owns 37,499 shares of the company’s stock valued at $1,474,000 after buying an additional 1,875 shares during the last quarter. New York State Common Retirement Fund boosted its position in Amedisys by 32.4% in the fourth quarter. New York State Common Retirement Fund now owns 91,345 shares of the company’s stock valued at $3,592,000 after buying an additional 22,365 shares during the last quarter. GSA Capital Partners LLP boosted its position in Amedisys by 20.3% in the fourth quarter. GSA Capital Partners LLP now owns 38,192 shares of the company’s stock valued at $1,502,000 after buying an additional 6,437 shares during the last quarter. Finally, Morgan Stanley boosted its position in Amedisys by 21.1% in the fourth quarter. Morgan Stanley now owns 330,210 shares of the company’s stock valued at $12,983,000 after buying an additional 57,461 shares during the last quarter.

Amedisys, Inc (Amedisys) is a provider of home health and hospice services. The Company offers home health services to the chronic, co-morbid, aging American population. The Company operates through three segments: home health, hospice and personal care. The Company’s home health segment delivers a range of services in the homes of individuals recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important personal tasks.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.